Inactive Instrument

Novavax, Inc. Stock price Nasdaq

Equities

US6700021040

Biotechnology & Medical Research

Sales 2024 * 852M Sales 2025 * 952M Capitalization 719M
Net income 2024 * -103M Net income 2025 * 35M EV / Sales 2024 * 0.35 x
Net cash position 2024 * 422M Net cash position 2025 * 297M EV / Sales 2025 * 0.44 x
P/E ratio 2024 *
-5.64 x
P/E ratio 2025 *
28.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.38%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 23-01-22
President 64 14-03-09
Director of Finance/CFO 58 21-08-15
Members of the board TitleAgeSince
Director/Board Member 57 22-10-28
Director/Board Member 58 20-10-31
Director/Board Member 58 20-06-15
More insiders
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Novavax, Inc.
  4. Stock Novavax, Inc. - Nasdaq